Semaglutide Long-Term Cardiovascular Effects Tracked in SELECT-LIFE Follow-Up Study
Background
The SELECT Cardiovascular Outcomes Trial investigated the cardiovascular benefits of semaglutide in individuals with overweight or obesity. While SELECT provided crucial short-to-medium term data, there remained a critical need to understand the long-term cardiovascular and metabolic impacts of semaglutide after treatment discontinuation.
Results
The SELECT-LIFE study is actively collecting data to assess the sustained effects of prior semaglutide exposure. It aims to gather comprehensive long-term health information from 3439 participants over a period extending until 2025. No specific outcome data from SELECT-LIFE are available yet, as the study is ongoing, but its design is a key finding. This follow-up will provide insights into how health outcomes compare between those previously on semaglutide versus placebo in the SELECT trial, post-intervention. The study's non-interventional nature allows for observation of real-world health trajectories. > This large-scale, non-interventional follow-up is crucial for understanding the real-world, long-term trajectory of cardiovascular health and weight management in individuals previously treated with semaglutide for obesity or overweight.
Why It Matters
This follow-up study is critical for understanding the sustained impact of semaglutide on cardiovascular health and weight management after treatment cessation. The insights gained could inform long-term treatment strategies and patient counseling for individuals with obesity and cardiovascular disease. Understanding these long-term effects is essential for guiding future clinical recommendations and potentially expanding the indications for semaglutide. The data collected will be vital for future meta-analyses and real-world evidence generation, potentially influencing public health guidelines.